Trinity Delta Lighthouse: Oxford BioDynamics
Trinity Delta view: Oxford BioDynamics’ near-term focus is on securing one or more partnerships, collaborations and licensing deals to maximise the revenue potential of its portfolio of innovative and clinically robust tests. In our view, the market opportunities for CiRT, PSE, and the EpiSwitch test portfolio remain intact and sizeable, but successful uptake requires continued significant commercial investment and/or partners. There are encouraging signs of growth in test volumes, notably PSE, and the potential early submission for CiRT guideline inclusion would also be a positive development. However, longer-term, in our view, sustainable test volume growth will require substantial ongoing commercial investment, and thus third-party partners or further funds are needed to deliver on this potential.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.